Clinical Trial: Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: The Use of Ranibizumab to Control Pterygium Growth in Recurrences and in Non-surgical Primary Lesions.
Brief Summary: Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Detailed Summary:
Ptergyia are chronic fibrovascular lesions of the ocular surface. This study is designed to look for a signal of efficacy when the lesions are in a phase of active vascular growth. This phase is most often caught in a newly recurring pterygia post-operatively.
Patients identified with actively growing lesions, will be offered local injections directly beneath the lesions. They will be examined for any adverse side effects and regression of the lesion.
Sponsor: University of New Mexico
Current Primary Outcome: Safety [ Time Frame: Within the first 30 days after injection ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Regression of pterygium [ Time Frame: Within 30 days after drug injection ]
Original Secondary Outcome: Same as current
Information By: University of New Mexico
Dates:
Date Received: July 23, 2010
Date Started: August 2010
Date Completion:
Last Updated: May 13, 2016
Last Verified: May 2016